​

Dissolving microneedles (DMNs) offer a minimally invasive, pain-free approach for transdermal drug delivery, enabling localized and sustained therapeutic effects. This study explores the incorporation of gemcitabine, a potent chemotherapeutic agent, into DMNs for enhanced cancer therapy. The microneedles are fabricated using biocompatible polymers, ensuring controlled dissolution upon skin insertion, facilitating the efficient release of gemcitabine directly into the interstitial fluid. This targeted delivery method minimizes systemic toxicity and enhances the drug’s bioavailability at the tumor site. Preliminary in vitro and in vivo studies demonstrate the potential of gemcitabine-loaded DMNs to improve therapeutic outcomes while reducing adverse effects, offering a promising alternative for cancer treatment.​